Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravesical BCG for prevention of postoperative recurrence in intermediate- and high-risk non-muscle-invasive bladder cancer
CTR20233873Phase 3Active
- Sponsor
- Kernal Biologics
- Start
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), Bladder cancer in situ (CIS) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Kernal Biologics. Primary endpoint: 1-year recurrence-free survival rate. Started Jan 2024; status: active.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)Bladder cancer in situ (CIS)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on CTR20233873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233873.